|
US10010543B1
|
|
Transdermal dosage form
|
|
WO2010008569A1
|
|
Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same
|
|
WO2009097156A1
|
|
Pharmaceutical capsules comprising extended release dipyridamole pellets
|
|
WO2008112245A1
|
|
Devices for determining the release profile of macromolecules and methods of using the same
|
|
US7811604B1
|
|
Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
|
|
BRPI0506195A
|
|
surface treated modafinil particles
|
|
US7390503B1
|
|
Ondansetron orally disintegrating tablets
|
|
WO2004098517A2
|
|
Methods of hormonal treatment utilizing extended cycle contraceptive regimens
|
|
US2004253308A1
|
|
Surface-treated modafinil particles
|
|
WO2004100064A2
|
|
Device for calculating anticipated days for menstruation
|
|
AU2004229565A1
|
|
Methods of administering estrogens and progestins
|
|
CA2515697A1
|
|
Process for the production of 2-oxa-3-one androstane derivatives
|
|
CA2502915A1
|
|
Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
|
|
US2004138180A1
|
|
Bisphosphonate composition and process for the preparation thereof
|
|
US2004222123A1
|
|
Kit for pharmaceuticals
|
|
US6992075B2
|
|
C(14) estrogenic compounds
|
|
EP1494679A1
|
|
Step-down estrogen therapy
|
|
CA2481309A1
|
|
Method of hormonal therapy
|
|
EP1390711A2
|
|
Patient compliance and monitoring system
|
|
AU2002232759B2
|
|
Methods and formulations for the treatment of female sexual dysfunction
|
